These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 1788299)

  • 21. Abnormalities of the electron transport chain in idiopathic Parkinson's disease.
    Parker WD; Boyson SJ; Parks JK
    Ann Neurol; 1989 Dec; 26(6):719-23. PubMed ID: 2557792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver enzyme abnormalities in Parkinson's disease.
    Tanner CM
    Geriatrics; 1991 Aug; 46 Suppl 1():60-3. PubMed ID: 1894148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What has been learnt from study of dopamine receptors in Parkinson's disease?
    Hurley MJ; Jenner P
    Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease.
    Dexter DT; Sian J; Rose S; Hindmarsh JG; Mann VM; Cooper JM; Wells FR; Daniel SE; Lees AJ; Schapira AH
    Ann Neurol; 1994 Jan; 35(1):38-44. PubMed ID: 8285590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Partial oxidation and oxidative polymerization of metallothionein.
    Haase H; Maret W
    Electrophoresis; 2008 Nov; 29(20):4169-76. PubMed ID: 18844317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mitochondrial oxidative phosphorylation defects in Parkinson's disease.
    Shoffner JM; Watts RL; Juncos JL; Torroni A; Wallace DC
    Ann Neurol; 1991 Sep; 30(3):332-9. PubMed ID: 1952821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy.
    Kikuchi A; Takeda A; Onodera H; Kimpara T; Hisanaga K; Sato N; Nunomura A; Castellani RJ; Perry G; Smith MA; Itoyama Y
    Neurobiol Dis; 2002 Mar; 9(2):244-8. PubMed ID: 11895375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olfactory mucosa is a potential source for autologous stem cell therapy for Parkinson's disease.
    Murrell W; Wetzig A; Donnellan M; Féron F; Burne T; Meedeniya A; Kesby J; Bianco J; Perry C; Silburn P; Mackay-Sim A
    Stem Cells; 2008 Aug; 26(8):2183-92. PubMed ID: 18535154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuromelanin and Parkinson's disease.
    Marsden CD
    J Neural Transm Suppl; 1983; 19():121-41. PubMed ID: 6321645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson's disease].
    Yoshino H; Hattori Y; Imai H; Narabayashi H; Chiba K
    Rinsho Shinkeigaku; 1993 Mar; 33(3):261-5. PubMed ID: 8334787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxidative damage in Parkinson's disease.
    Sherer TB; Greenamyre JT
    Antioxid Redox Signal; 2005; 7(5-6):627-9. PubMed ID: 15890006
    [No Abstract]   [Full Text] [Related]  

  • 32. Neuroproteomics and Parkinson's disease: don't forget human samples.
    Licker V; Burkhard PR
    Expert Rev Proteomics; 2011 Jun; 8(3):291-4. PubMed ID: 21679108
    [No Abstract]   [Full Text] [Related]  

  • 33. [Dysfunctions of potassium channels and Parkinson's disease].
    Wang G; Chen SD
    Sheng Li Ke Xue Jin Zhan; 2008 Jan; 39(1):57-60. PubMed ID: 18357691
    [No Abstract]   [Full Text] [Related]  

  • 34. Metallothionein as a therapeutic molecular target against human diseases.
    Inoue K; Satoh M
    Curr Pharm Biotechnol; 2013; 14(4):391-3. PubMed ID: 24568670
    [No Abstract]   [Full Text] [Related]  

  • 35. Role of iron and oxidant stress in the normal and parkinsonian brain. Proceedings of a symposium. Sarasota, Florida, November 14-17, 1991.
    Ann Neurol; 1992; 32 Suppl():S1-145. PubMed ID: 1354953
    [No Abstract]   [Full Text] [Related]  

  • 36. Commentary on 'Toxicity of Aminochromes'.
    Graham DG
    Toxicol Lett; 1989 Jul; 48(1):1-2. PubMed ID: 2749776
    [No Abstract]   [Full Text] [Related]  

  • 37. Mapping brain metals to evaluate therapies for neurodegenerative disease.
    Popescu BF; Nichol H
    CNS Neurosci Ther; 2011 Aug; 17(4):256-68. PubMed ID: 20553312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metallothionein and oxidation reactions in Parkinson's disease.
    Ebadi M; Pfeiffer RF; Murrin LC; Shiraga H
    Proc West Pharmacol Soc; 1991; 34():285-90. PubMed ID: 1788299
    [No Abstract]   [Full Text] [Related]  

  • 39. Metallothionein provides ubiquinone-mediated neuroprotection in Parkinson's disease.
    Ebadi M; Sharma S; Muralikrishnan D; Shavali S; Eken J; Sangchot P; Chetsawang B; Brekke L
    Proc West Pharmacol Soc; 2002; 45():36-8. PubMed ID: 12434520
    [No Abstract]   [Full Text] [Related]  

  • 40. Mitochondrial oxidative phosphorylation defects in Parkinson's disease.
    Wallace DC; Shoffner JM; Watts RL; Juncos JL; Torroni A
    Ann Neurol; 1992 Jul; 32(1):113-4. PubMed ID: 1642467
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.